Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.1000 (-0.94%) ($2.0900 - $2.1800) on Tue. Mar. 15, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.59% (three month average) | RSI | 30 | Latest Price | $2.1000(-0.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.7% a day on average for past five trading days. | Weekly Trend | HTBX declines -5.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(57%) VWO(55%) CEMB(52%) FXI(51%) IPO(51%) | Factors Impacting HTBX price | HTBX will decline at least -2.295% in a week (0% probabilities). VXX(-69%) UUP(-30%) TBT(-22%) USO(4%) EDOC(4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.295% (StdDev 4.59%) | Hourly BBV | -0.7 () | Intraday Trend | 0.5% | | | |
|
1 - 5 Day Possible Target | $-12.96(-717.14%) | Resistance Level | $2.48 | 5 Day Moving Average | $2.28(-7.89%) | 10 Day Moving Average | $2.33(-9.87%) | 20 Day Moving Average | $2.48(-15.32%) | To recent high | -48.5% | To recent low | 0% | Market Cap | $231m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |